Therapeutics

New gene therapy well-tolerated and improves hearing in all 10 patients with congenital deafness or severe hearing impairment

New findings could lead to better cancer immunotherapies by helping develop new drugs or T cell treatments to boost immune response

Strategic collaboration to innovate Treg and TIL therapies, streamline cell therapy workflows, and enhance manufacturing efficiency

From precision oncology to gene editing, these standout trials could redefine how we diagnose and treat rare diseases and cancer

Strategies and standards that help clinical labs strengthen compliance, ensure weighing accuracy, and protect data integrity

The Today's Clinical Lab 2025 Cancer & Precision Medicine print issue features cancer screening successes, emerging technologies, and advances in targeted treatments

Inherited retinal diseases cause vision loss and blindness. New gene therapy trials have improved sight for some

The bright, new future of therapeutic epigenome editing is already on our doorstep

New breakthrough from Memorial Sloan Kettering Cancer Center shows how off-the-shelf CAR T cells from healthy donors can be modified to fight cancer without immune rejection

In vitro libraries have recently demonstrated the ability to deliver antibodies with affinities comparable to those obtained by immunization

Julie Schulz, MD, MPH, discusses GLP-1 receptor agonists, the lab’s role in prescribing, and the future of the GLP-1 drug industry 

Potential new therapy for childhood brain cancer is effective in infiltrating, killing tumor cells in preclinical models in mice

OKN4395 is the first compound to be developed using K1.0, Owkin’s AI-powered operating system

The study identified several drugs already licensed and in use that have the potential to be repurposed to treat dementia.

Ensure precision and compliance in fluid delivery with insights into advanced testing techniques and technologies

Solutions for mitigating error and improving precision in dose accuracy testing

C. Ola Landgren and colleagues discuss adapting to a field transformed by new immunotherapy drugs and targeted therapies and how to best combine treatments

Two clinical trials testing loncastuximab tesirine in patients with high-risk follicular lymphoma or with rare, marginal zone lymphoma show encouraging results

In a novel study of front-line providers, the psychedelic drug reduced symptoms of depression more effectively than a placebo

Screening successes, emerging technologies, precision treatments, and other steps forward from the AACR Cancer Progress Report 2024